We advise oncology sponsors on the decisions between first data and first patient.
We work with biotechnology and pharmaceutical teams developing cancer therapies in the U.S. and India.
Practices
Clinical Asset Development
Helping sponsors decide whether and how an oncology asset moves into the clinic, then seeing that decision through regulatory review and study start-up.
Oncology KOL Advisory
Bringing experienced oncologists, investigators and former regulators to a program while its protocol can still change.
How we work
Assess
We review the asset, the data and the options available.
Decide
We agree the go/no-go and the pathway against clear criteria.
Prepare
We build the dossier and prepare the team for review.
Deliver
We stay involved through submission and first patient in.
People
Stephane Marzabal, PhD
Program leadership and governance
Roland Winger
Global clinical programs
Dr. Balram Bhargava
Advisor, former Director-General, ICMR
Insights
Tissue Is the Trial: Why Biomarker-Gated Oncology Studies Fail on Logistics
September 18, 2026
Rule 101, Decoded: When Your FDA Dossier Can Skip a Phase 3 in India
September 10, 2026
